Surg­ing ahead in the RSV race, Pfiz­er buys out a PhII play­er in $525M M&A pact

4 years ago
Deals

Spot­ting a gem from transpa­cif­ic biotech, As­traZeneca pays $25M cash to pick up a pre­clin­i­cal bis­pe­cif­ic an­ti­body

4 years ago
Deals
China

Phar­ma IP in view as new USP­TO di­rec­tor Kathi Vi­dal wins Sen­ate con­fir­ma­tion

4 years ago
Pharma

Fol­low­ing $1.9B buy­out, Sanofi shut­ters Kad­mon's NY site and chops 25 staffers

4 years ago
Pharma

Catal­ent wins bid­ding war to take on UK's VMIC

4 years ago
Pharma
Manufacturing

Eu­rope holds off on a fourth Covid vac­cine shot for those un­der the age of 80

4 years ago
Coronavirus

Seres qui­et­ly dis­clos­es it has once again al­tered plans in ul­cer­a­tive col­i­tis

4 years ago
R&D

Co-founder of Flori­da phar­ma in­dict­ed af­ter mul­ti­state bac­te­r­i­al out­break at chil­dren's hos­pi­tals

4 years ago
Pharma
Manufacturing

John­son & John­son dri­ves pe­riph­er­al artery dis­ease aware­ness in new ‘Save Legs’ ini­tia­tive

4 years ago
Pharma
Marketing

Min­neso­ta judge nar­rows charges in class ac­tion suit against My­lan, phar­ma­cy ben­e­fit man­agers over EpiPen price hikes

4 years ago
Pharma

A new an­ti-ag­ing biotech wants to add 10 years to your life. But who's fund­ing it?

4 years ago
Financing
Startups

Psych and neu­ro R&D notch a win as BioX­cel gets FDA ap­proval for schiz­o­phre­nia, bipo­lar dis­or­der-re­lat­ed ag­i­ta­tion

4 years ago
AI
FDA+

FDA's court-man­dat­ed re­lease of Pfiz­er Covid-19 vac­cine doc­u­ments con­tin­ues to turn over few sur­pris­es

4 years ago
FDA+
Coronavirus

5AM dash­es out of the gate, kick­ing off Q2 with $750M in two new funds

4 years ago
Financing

FDA halts the use of GSK's Covid-19 drug com­plete­ly as BA.2 sub­vari­ant blan­kets the coun­try

4 years ago
FDA+
Coronavirus

Build­ing on its reti­nal dis­ease ex­per­tise, Re­gen­eron signs eye-fo­cused gene ther­a­py pact with Ger­man biotech

4 years ago
Deals

No­var­tis' PI3K drug, al­ready ap­proved in breast can­cer, nabs a speedy OK to treat ul­tra-rare con­di­tion

4 years ago
Pharma
FDA+

As part of broad­er gene ther­a­py am­bi­tions, Take­da links up again with a small Chica­go biotech

4 years ago
Startups
Pharma

Af­ter Covid-19 suc­cess, pa­tients with the world’s ‘most stig­ma­tized’ in­fec­tion push for their own Op­er­a­tion ...

4 years ago
In Focus

'S­tuck in the past': Athi­ra hits back at bil­lion­aire backer and his bid to put oust­ed CEO Leen Kawas back in the ...

4 years ago
People

Scoop: One of Phil Krause’s post-FDA gigs, a biotech try­ing to de­vel­op a Shin­grix com­peti­tor, goes up for sale

4 years ago
People
Startups

Fresh off an $11.5B car­dio wa­ger, Mer­ck promis­es in­vestors a megablock­buster fu­ture in a re­turn to the glo­ry days

4 years ago
Pharma

The bill on Mer­ck­'s C-suite shake­up in­cludes about $30M for dual CEO pay pack­ages

4 years ago
People
Pharma

No­var­tis man­u­fac­tur­ing fa­cil­i­ty in North Car­oli­na gets FDA all-clear to pro­duce, ship gene ther­a­pies

4 years ago
Pharma
Manufacturing
First page Previous page 544545546547548549550 Next page Last page
A service from the Financial Times